HC Wainwright restated their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright also issued estimates for Repare Therapeutics’ Q4 2023 earnings at $0.02 EPS, FY2023 earnings at ($1.55) EPS, […]
Repare Therapeutics Inc. (NASDAQ:RPTX – Free Report) – Analysts at HC Wainwright boosted their FY2023 earnings per share (EPS) estimates for shares of Repare Therapeutics in a research note issued to investors on Monday, November 20th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($1.55) for the […]
RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies
RP-3467 demonstrated complete, sustained regressions.
Repare Therapeutics Inc. disclosed polo-like kinase 4 as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company?s Pol? inhibitor,.